Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
KYTX
Stock Latest News
Company Announcements
Kyverna Therapeutics Holds 2025 Annual Stockholders Meeting
25d ago
8K
KYTX
Premium
Weekend Updates
Kyverna, Rocket, Teva, Fair Isaac, Oklo Trending by Analysts
29d ago
FICO
KYTX
Premium
Ratings
Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases
1M ago
KYTX
Premium
Ratings
Kyverna Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position
1M ago
KYTX
Premium
The Fly
Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
1M ago
KYTX
Premium
Ratings
Kyverna Therapeutics: Strong Clinical Progress and Regulatory Alignment Support Buy Rating
1M ago
KYTX
Premium
Company Announcements
Kyverna Therapeutics Reports Q1 2025 Progress and Outlook
2M ago
KYTX
Premium
Ratings
Kyverna Therapeutics: Strategic Advancements and Clinical Progress Drive Buy Rating
2M ago
KYTX
Premium
The Fly
Kyverna Therapeutics reports Q1 EPS ($1.03), consensus ($1.00)
2M ago
KYTX
Premium
The Fly
Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
3M ago
KYTX
Premium
The Fly
Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley
3M ago
KYTX
Premium
Ratings
Kyverna Therapeutics: Strategic Advancements and Robust Financial Health Underpin Buy Rating
3M ago
KYTX
Premium
The Fly
Kyverna Therapeutics price target lowered to $12 from $13 at UBS
3M ago
KYTX
Premium
Company Announcements
Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
3M ago
KYTX
Premium
The Fly
Kyverna Therapeutics files $250M mixed securities shelf
3M ago
KYTX
Premium
The Fly
Kyverna Therapeutics sees cash and securities sufficient into 2027
3M ago
KYTX
Premium
The Fly
Kyverna appoints Naji Gehchan as Chief Medical and Development Officer
5M ago
LLY
KYTX
Premium
Company Announcements
Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth
6M ago
8K
KYTX
Premium
The Fly
Kyverna Therapeutics announces senior leadership appointments
7M ago
KYTX
Premium
Class Action
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP
7M ago
KYTX
Premium
The Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
7M ago
ALLO
IGMS
Premium
The Fly
Kyverna shares remain ‘significantly under-valued,’ says JPMorgan
7M ago
KYTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
